3BNC117 antibody: Clinical Trials

7 trials of 3BNC117 antibody, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 3 unknown. 7 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 27Completed 4, Unknown 3

Follow 3BNC117 antibody: new trials by email Literature Review of 3BNC117 antibody trials Research Report on 3BNC117 antibody

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection
Albuvirtide, 3BNC117 Antibody - HIV/AIDS
Phase 2UnknownFrontier Biotechnologies Inc.202021-11-302021-09-29
Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection
Albuvirtide, 3BNC117 - HIV/AIDS
Phase 2UnknownFrontier Biotechnologies Inc.242021-05-012021-03-26
Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects
Albuvirtide, 3BNC117, Baseline ART - HIV-1-infection
Phase 2UnknownFrontier Biotechnologies Inc.802018-12-172021-09-29
Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART
Romidepsin, 3BNC117, Antiretrovirals - Hiv
Phase 2CompletedAarhus University Hospital602017-01-202025-04-18
Romidepsin Plus 3BNC117 Phase 2a Study
3BNC117, Romidepsin - Human Immunodeficiency Virus (HIV)
Phase 2CompletedRockefeller University482017-01-062022-07-14
A Study of the Safety and Antiretroviral Activity of 3BNC117
3BNC117, Antiretroviral Treatment Interruption - HIV-1 Infection
Phase 2CompletedRockefeller University172015-10-012021-06-16
3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption
3BNC117, ART Interruption - HIV-1 Infection
Phase 2CompletedRockefeller University162015-03-112020-07-23

Conditions studied

Acquired Immunodeficiency Syndrome (4)

Sponsors

Frontier Biotechnologies Inc. (3)  ·  Rockefeller University (3)  ·  Aarhus University Hospital (1)

Countries

United States (5)  ·  Denmark (2)  ·  China (1)  ·  Germany (1)  ·  United Kingdom (1)

Top investigators

Marina Caskey, MD (3)  ·  Cheng Yao (1)  ·  Cheng Yao, M.D. (1)

Results publications

PMID 32838558, PMID 35544074, PMID 36253609, PMID 41896772

NIH funding

2015 (1), U01AI118536 (1)